Name your favorite Pfizer Blunder in the last 15 years

Discussion in 'Pfizer' started by Anonymous, Jun 28, 2010 at 11:24 PM.

  1. anonymous

    anonymous Guest

    Agreed, Pfizer was a sinking ship and he was questioned on CNBC, “ why would your board give you a30% boost in compensation,when the companies performance is way under par” His Answer? “ the board decided that is what they needed to offer to keep me with the company” WHAT????!! The board surely were not fiduciary like were they? Then he walks away with a 200 million package! Btw emplyess we’re given a 1% raise that year if they were lucky!
     

  2. anonymous

    anonymous Guest

    OMG, so true!! He was such a horrible rep and could not sell his way out of a paper bag! He was in the right place at the right time and he was the right skin tone! He is now making over $300000! Life is good for Mr. Brown!!!
     
  3. anonymous

    anonymous Guest

    how can you beat the current situation? Company at the forefront of ending Covid, getting people back to normal, take in tens of billions...the very next year we lose money in a quarter, cutting $3.5 bit, closing plants and laying thousands off. Hard to top that, thanks Albert!
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    It’s a very large investment company that dabbles in pharmaceuticals
     
  6. anonymous

    anonymous Guest

    Cutting therapeutic areas of R and D such as cardiology and neuroscience. Guess how many products we have developed in house since Viagara. Hint: Not much more than zero. When CEO says we have one of largest R and D budgets who cares? It is like Callahan brake pads taking a dump in a box with a guarantee.
     
  7. anonymous

    anonymous Guest

    LOL these posts are great!! Thank you for reminding me how much a Delusional this company is and yet on LinkedIn you have department heads trying to pretend how important their work is.. stock is going to 25 next… yet there will be people still trying to sell this pig w/ lip stick.
     
  8. anonymous

    anonymous Guest

    The company does make real money.

    Despite all of the so-called blunders, it’s always Pfizer that is on the shopping spree for new products and companies large and small to devour.

    I get a kick out of this thread but let’s not turn acquired companies into martyrs and pretend they were doing so great before the acquisition. They weren’t doing well enough to avoid an acquisition. A few got rich off of it so they’re not complaining.

    The biggest blunder in my opinion is simply not being more honest with employees about being much less of a growth stock and being more of a dividend income play.
     
  9. anonymous

    anonymous Guest

    By far, the biggest blunder is how they mismanaged Covid vaccine and treatment. Pfizer never set a great message about mRNA technology, allowing fear and misinformation to proliferate. Pfizer never set an expectation about the vaccine as individual protection that helps the vaccinated person to fight off the worse effects of the virus. Pfizer allowed politicians, bureaucrats and pundits to overpromise the protection extended to others. People are confused and no longer find it essential to trust the Covid vaccine, or even other vaccines that are well established. It will be interesting to see how the flu vaccine season pans out for 2023-24.

    Just as bad, Pfizer did not manage the Covid revenue windfall and continued to overpromise future sales. Pfizer leadership created an additional revenue cliff that continues to gnaw away at PFE stock price.

    Worse of all, Pfizer mismanagement of the entire scenario will create caution among other companies when another pandemic arises. I assume that pharma companies today are debating the science of stepping into rapidly emerging, and perhaps rapidly disappearing, opportunities while the financial teams are building the argument against it. Pfizer’s boasts of Science Will Win (slogan with no definition) and being a great humanitarian company fall flat as they have set an awful example of how pandemic “saviors” can quickly become Wall Street flops.
     
  10. anonymous

    anonymous Guest

    Along with Exubera... buying King Pharma and relaunching Embeda!
     
  11. anonymous

    anonymous Guest

    Including an SV40 promoter sequence into the mRNA in the COVID jabs, and then hiding it from regulators. And employing CROs incapable removing DNA plasmids from the product.

    Once the lawsuits get underway, PFE stock is dead. It’s going to make roundup look like chicken feed.
     
  12. anonymous

    anonymous Guest

    If this is accurate and has basis, they will do two things
    First, say that in humanitarian interests and “light speed moon shot” focus, they did all possible to thwart the terrible virus
    Second, blame BioNTech
     
  13. anonymous

    anonymous Guest

    We could cut all new drug research and get just about as much out of our R&D programs...Zero